Clinical trials: PET-CT
Esophageal Cancer, Gastric Cancer (GC)
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric…
- Conditions
- Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Trial name
- FAPI-GO (NCT07217704)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- SOFIE
Rectal Cancer, Lymph Node Metastases
FDG - PET / MRI in Patients With Rectal Cancer
The combination of FDG-PET/CT and MRI at staging of rectal cancer in diagnosis is currently very little studied. The investigator have a unique opportunity to study this.
- Trial name
- RECTOPET (NCT03846882)
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Västerbotten
Healthy Volunteers From Racial/Ethnic Minority Populations
EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations
The objective of this pilot study is to collect preliminary data using total body scans on a new, first of its kind, FDA 510k-cleared positron emission tomography/computed tomography (PET/CT) scanner, called EXPLORER.
- Trial name
- NCT04812080
- Testing
- EXPLORER PET/CT
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Uterine Cervical Neoplasms, Endometrial Neoplasms
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
[F-18] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts.
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms
- Trial name
- NCT01717391
- Testing
- fluorothymidine F 18
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- John M. Buatti
PET/CT Imaging
Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT
The purpose of this study is to assess new low radiation dose techniques for clinical PET/CT scans through intra-individual comparison between a clinical, standard dose scan and a low-dose scan, completed within one week of each…
- Trial name
- NCT03519659
- Testing
- PET/CT scan with 13 mCi radiation dose, PET/CT scan with 5 mCi radiation dose, PET/CT scan with 2.5 mCi radiation dose
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Cincinnati
Covid19, SARS-CoV Infection
Imaging Immune Activation in COVID-19
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent…
- Trial name
- NCT04815096
- Testing
- [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- CellSight Technologies, Inc.
Presence of COVID-19 Compatible CT Abnormalities
CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients
CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i)…
- Trial name
- NCT04512118
- Testing
- PET-CT of 18F-FDG
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Central Hospital, Nancy, France
SAPHO Syndrome
Characterizing SAPHO With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation.
- Trial name
- NCT04596462
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer, Pancreatitis
TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Aim of the prospective study is a better differentiation of benign and malignant lesions in the pancreas in patients with suspected pancreatic cancer using images 30 and 90 min p.i.
- Conditions
- Pancreatic Cancer, Pancreatitis, IPMN
- Trial name
- TOF-P (NCT03914950)
- Testing
- PET/CT results with TOF/without TOF
- Volunteers
- 174 people
- Sponsor
- Medical University of Graz
Recurrent Prostate Carcinoma
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after…
- Trial name
- PSMA SRT (NCT03582774)
- Testing
- Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 193 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
[18F]PSMA-11 PET/CT Phase 3 Clinical Study
Prostate cancer (PCa) is the most frequently occurring male cancer in Belgium. After treatment with surgery and/or radiotherapy, almost half of the patients suffer from a tumor recurrence, often diagnosed by an increase in serum…
- Trial name
- NGP3 (NCT03911310)
- Testing
- [18F]PSMA-11, [68Ga]PSMA-11
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- University Hospital, Ghent
Triple Negative Breast Cancer
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC)…
- Trial name
- OPALESCENCE (NCT04758780)
- Testing
- 89Zr-TLX250
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Institut Cancerologie de l'Ouest
Neuroendocrine Tumors
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
- Trial name
- NCT03673943
- Testing
- 64Cu-DOTATATE
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Radiomedix, Inc.
Cervical Cancer
Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer
RATIONALE: Diagnostic procedures, such as fluorine F 18 EF5 PET/CT imaging, may help find oxygen in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00978874
- Testing
- fludeoxyglucose F 18, fluorine F 18 EF5
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer, Bone Metastases
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
A phase1 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
- Trial name
- NCT02826382
- Testing
- [68Ga]P15-041
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Five Eleven Pharma, Inc.
Fever of Unknown Origin
PLACE OF THE 18F-FDG-PET/CT IN THE DIAGNOSTIC WORKUP IN PATIENTS WITH CLASSICAL FEVER OF UNKNOWN ORIGIN (FUO)
Objective : To explore the diagnostic contribution of the 18F-FDG-PET/CT in a population of patients with classical fever of unknown origin (FUO), to precise its place in the diagnostic decision tree in a real-life setting and to…
- Trial name
- NCT04851379
- Where
- France
- Volunteers
- 44 people
- Sponsor
- University Hospital, Montpellier
Colorectal Cancer
Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT
Measuring tumor response to treatment based on computed tomography (CT) and/or magnetic resonance imaging (MRI) has been a widely debated issue (response criteria in solid tumors [RECIST] and World Health Organization criteria).
- Trial name
- RESCORE (NCT00823810)
- Testing
- PET/CT
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Turku University Hospital
Prostate Cancer
PET-CT/MRI in the Radiotherapy for Prostate Cancer
The trial is to explore new and effective techniques in the treatment of prostate cancer and evaluate the role of PET-CT / MRI played in radiotherapy.
- Trial name
- NCT02816840
- Testing
- PET-CT, PET-MRI
- Volunteers
- 90 people
- Sponsor
- Xuzhou Medical University
Atherosclerosis, Complications of Diabetes Mellitus
18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes
Coronary artery calcification is a sign of heart disease. A nuclear medicine PET-CT test using sodium fluoride (18F-NaF) radioisotope has been shown to help identify growing calcification plaques early on in the disease process.
- Trial name
- D-NaF (NCT03530176)
- Testing
- 18Fluoride-Sodium Fluoride radio-isotope
- Where
- Canada
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Pheochromocytoma, Paraganglioma
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment.
- Trial name
- NCT05636540
- Testing
- [18F]FluorThanatrace ([18F]FTT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Heather Wachtel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.